Trials / Completed
CompletedNCT05615532
A Relative Bioavailability Study of LY3209590 in Healthy Participants
Effect of Injection Site on the Relative Bioavailability of Single Dose of LY3209590 and Evaluation of Absolute Bioavailability of LY3209590 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study will be conducted in two parts (part A and part B). The main purpose of this study is to compare the amount of LY3209590 that gets into the blood stream and how long it takes the body to get rid of it, when self-administered at different body sites, abdominal wall, upper arm and thigh (part A), when administered by two different routes of injection, subcutaneously or intravenously (part B) in healthy participants. The study may last up to 65 (part A) and 184 (part B) days, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 (SC) | Administered SC. |
| DRUG | LY3209590 (IV) | Administered IV. |
Timeline
- Start date
- 2022-11-11
- Primary completion
- 2023-06-28
- Completion
- 2023-06-28
- First posted
- 2022-11-14
- Last updated
- 2024-06-12
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05615532. Inclusion in this directory is not an endorsement.